Volume 115, Issue 3 pp. 243-249
Research Article

Clinical auditing as an instrument for quality improvement in breast cancer care in the Netherlands: The national NABON Breast Cancer Audit

Annelotte C.M. van Bommel MD

Corresponding Author

Annelotte C.M. van Bommel MD

Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands

Dutch Institute for Clinical Auditing, Leiden, The Netherlands

Correspondence to: Annelotte C.M. van Bommel, MD, Department of Surgery, K6R, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, The Netherlands. Fax: 0031-71-526 6750. E-mail: [email protected]

Search for more papers by this author
Pauline E.R. Spronk MD

Pauline E.R. Spronk MD

Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands

Dutch Institute for Clinical Auditing, Leiden, The Netherlands

Search for more papers by this author
Marie-Jeanne T.F.D. Vrancken Peeters MD, PhD

Marie-Jeanne T.F.D. Vrancken Peeters MD, PhD

Department of Surgery, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, The Netherlands

Search for more papers by this author
Agnes Jager MD, PhD

Agnes Jager MD, PhD

Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, The Netherlands

Search for more papers by this author
Marc Lobbes MD, PhD

Marc Lobbes MD, PhD

Department of Radiology, Maastricht University Medical Centre, Maastricht, The Netherlands

Search for more papers by this author
John H. Maduro MD, PhD

John H. Maduro MD, PhD

Department of Radiation Oncology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands

Search for more papers by this author
Marc A.M. Mureau MD, PhD

Marc A.M. Mureau MD, PhD

Department of Plastic and Reconstructive Surgery, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, The Netherlands

Search for more papers by this author
Kay Schreuder MSc

Kay Schreuder MSc

Department of Research, Comprehensive Cancer Organisation the Netherlands (IKNL), Utrecht, The Netherlands

Search for more papers by this author
Carolien H. Smorenburg MD, PhD

Carolien H. Smorenburg MD, PhD

Department of Medical Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, The Netherlands

Search for more papers by this author
Janneke Verloop MD, PhD

Janneke Verloop MD, PhD

Department of Research, Comprehensive Cancer Organisation the Netherlands (IKNL), Utrecht, The Netherlands

Search for more papers by this author
Pieter J. Westenend MD, PhD

Pieter J. Westenend MD, PhD

Department of Pathology, Laboratory for pathology Dordrecht e.o., Dordrecht, The Netherlands

Search for more papers by this author
Michel W.J.M. Wouters MD, PhD

Michel W.J.M. Wouters MD, PhD

Dutch Institute for Clinical Auditing, Leiden, The Netherlands

Department of Surgery, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

Search for more papers by this author
Sabine Siesling PhD

Sabine Siesling PhD

Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands

Department of Health Technology and Services Research, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands

Search for more papers by this author
Vivianne C.G. Tjan - Heijnen PhD

Vivianne C.G. Tjan - Heijnen PhD

Department of Medical Oncology, Maastricht University Medical Centre, GROW—School for Oncology and Developmental Biology, Maastricht, The Netherlands

Search for more papers by this author
Thijs van Dalen MD, PhD

Thijs van Dalen MD, PhD

Department of Surgery, Diakonessenhuis Utrecht, Utrecht, The Netherlands

Search for more papers by this author
On behalf of the NABON Breast Cancer Audit

On behalf of the NABON Breast Cancer Audit

Search for more papers by this author
First published: 25 November 2016
Citations: 66
Conflict of interest: None.
Funding: None.

Abstract

Background

In 2011, the NABON Breast Cancer Audit (NBCA) was instituted as a nation-wide audit to address quality of breast cancer care and guideline adherence in the Netherlands. The development of the NBCA and the results of 4 years of auditing are described.

Methods

Clinical and pathological characteristics of patients diagnosed with invasive breast cancer or in situ carcinoma (DCIS) and information regarding diagnosis and treatment are collected in all hospitals (n = 92) in the Netherlands. Thirty-two quality indicators measuring care structure, processes and outcomes were evaluated over time and compared between hospitals.

Results

The NBCA contains data of 56,927 patients (7,649 DCIS and 49,073 invasive cancers). Patients being discussed in pre- and post-operative multidisciplinary team meetings improved (2011: 83% and 91%; 2014: 98% and 99%, respectively) over the years. Tumour margin positivity rates after breast-conserving surgery for invasive cancer requiring re-operation were consistently low (∼5%). Other indicators, for example, the use of an MRI-scan prior to surgery or immediate breast reconstruction following mastectomy showed considerable hospital variation.

Conclusions

Results shown an overall high quality of breast cancer care in all hospitals in the Netherlands. For most quality indicators improvement was seen over time, while some indicators showed yet unexplained variation. J. Surg. Oncol. 2017;115:243–249. © 2016 Wiley Periodicals, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.